Notably, 5a-HSA did not reduce nuclear p-SMAD2/3 expression in the adjacent non-neoplastic “healthy” liver, indicating that 5a-HSA could reduce TGFβ activation only in the tumor microenvironment (Fig. 5H). The gene discussed is TGFB1; the disease is neoplasm.